Disclosure of Invention
Based on the technical problems in the background technology, the invention provides the trimebutine maleate resin compound sustained-release suspension and the preparation method thereof, and the trimebutine maleate resin compound sustained-release suspension can realize positioning sustained release in human intestinal tracts, continuously exert drug effects, has good stability, has no bitter taste and improves the taking compliance of patients.
The invention provides a sustained-release suspension of a trimebutine maleate resin compound, which comprises, by weight, 190-210 parts of the trimebutine maleate resin compound, 18-22 parts of xanthan gum, 0-20 parts of tragacanth gum, 15-17 parts of citric acid, 4-6 parts of propylene glycol and 240-260 parts of water.
Preferably, the resin used for the trimebutine maleate resin complex is a cation exchange resin.
Preferably, the resin used for the trimebutine maleate resin complex isIRP88 resin.
Preferably, the method comprises the steps of,The particle size of IRP88 resin is 400-600 μm.
Preferably, in the preparation process of the trimebutine maleate resin compound, the trimebutine maleate solution and the resin are uniformly mixed, stirred for 0.8-1.2h at 37-40 ℃, subjected to solid-liquid separation, washed and dried to obtain the trimebutine maleate resin compound.
Preferably, in the preparation process of the trimebutine maleate resin compound, the weight ratio of the trimebutine maleate to the resin is 3-5:0.5.
Preferably, the concentration of the trimebutine maleate solution is 30-50mg/ml during the preparation of the trimebutine maleate resin complex.
Preferably, in the preparation process of the trimebutine maleate resin complex, the solvent of the trimebutine maleate solution is 15-25% acetonitrile water solution by volume fraction.
Preferably, the suspension further comprises sweetener, preservative, essence and pigment.
Preferably, the weight ratio of the xanthan gum to the sweetener, the preservative, the essence and the pigment is 18-22:4-6:0.5-1.5:0.5-1.5:0.5-1.5.
The sweetener may be aspartame, etc. The preservative may be methylparaben or the like. The essence can be lemon essence, etc. The pigment may be lemon yellow, etc.
The invention also provides a preparation method of the trimebutine maleate resin compound sustained-release suspension, which comprises the following steps of dissolving xanthan gum and tragacanth in water, sequentially adding citric acid and propylene glycol, uniformly mixing, adding the trimebutine maleate resin compound, and uniformly stirring to obtain the trimebutine maleate resin compound sustained-release suspension.
Preferably, the trimebutine maleate resin complex is added and stirred at a speed of 250-350rpm for 20-40min to mix well.
The water may be deionized water or the like.
1. The invention selects cation exchange resin and trimebutine maleate to form a compound, and the release of the drug depends on the ion type and strength due to the characteristics of the ion exchange resin, and the drug can not be released in an ion-free water system medium, thus ensuring the stability of the suspension;
2. The invention selects cation exchange resin and trimebutine maleate to form a compound, can mask the bitter taste of the trimebutine maleate, can further mask the bitter taste to improve the compliance of taking, has controllable particle size, can avoid the problems of different particle sizes of the traditional pellets, easy sedimentation and the like when being prepared into the suspension, and improves the stability of the suspension.
The trimebutine maleate resin compound sustained-release suspension can realize positioning sustained-release in human intestinal tracts, continuously exert drug effects, has good stability, does not have bitter taste, and improves the taking compliance of patients.
Detailed Description
The technical scheme of the invention is described in detail through specific embodiments.
Example 1
The preparation method of the trimebutine maleate resin compound comprises the following steps:
3g of trimebutine maleate raw material is added into 100ml of acetonitrile water solution with volume fraction of 20%, three parts are prepared in parallel, and 0.5g of trimebutine maleate raw material is added respectivelyIRP64 resin,IRP69 resin,IRP88 resin, stirring reaction at 25 ℃ for static drug loading, sampling at different time points, filtering for dilution, measuring absorbance by UV-vis, and calculating drug concentration and drug loading Q-infinity (mg.mg-1). The results are shown in FIG. 1. FIG. 1 shows the drug loading results for different resins.
As can be seen from fig. 1: the IRP88 resin has the highest drug loading rate and the highest rate of achieving drug loading balance.
Example 2
The preparation method of the trimebutine maleate resin compound comprises the following steps:
to 100ml of a 20% volume fraction acetonitrile aqueous solution were added 3g of trimebutine maleate raw material and 0.5g ofIRP64 resin was prepared in triplicate, and the static drug loading was performed by stirring the reaction at 25 ℃,37 ℃ and 40.0 ℃ respectively, sampling was performed at different time points, filtration was performed for dilution, absorbance was measured with UV-vis, and drug concentration and drug loading Q-infinity (mg·mg-1) were calculated. The results are shown in FIG. 2. Fig. 2 shows drug loading results at different temperatures.
As can be seen from FIG. 2, the drug loading and drug loading rate were faster at a temperature of 40.0 ℃.
Example 3
The preparation method of the trimebutine maleate resin compound comprises the following steps:
To 100ml of a 20% by volume acetonitrile aqueous solution was added 0.5gIRP64 resin is prepared in three parts in parallel, 1g, 3g and 5g of trimebutine maleate raw materials are respectively added, the mixture is stirred and reacted at 40.0 ℃ to carry out static drug loading, sampling is carried out at different time points, filtration and dilution are carried out, the absorbance is measured by using UV-vis, and the drug concentration and the drug loading quantity Q infinity (mg.-1) are calculated. The results are shown in FIG. 3. Fig. 3 shows the drug loading results for various amounts of trimebutine maleate.
As can be seen from FIG. 3, the drug loading and drug loading rate were higher when the concentration of trimebutine maleate was 30mg/ml, and the drug loading and drug loading efficiency were substantially the same as 30mg/ml when the concentration was 50 mg/ml.
As can be seen from examples 1 to 3, the conditions for preparing the trimebutine maleate resin composition are that the trimebutine maleate concentration is 30-50mg/ml and the resin isIRP88 resin, trimebutine maleate at 37-40 ℃ and resin at a weight ratio of 3-5:0.5.
Example 4
The sustained-release trimebutine maleate resin compound suspension comprises, by weight, 200 parts of trimebutine maleate resin compound, 20 parts of xanthan gum, 16 parts of citric acid, 5 parts of propylene glycol, 5 parts of aspartame, 1 part of methylparaben, 1 part of lemon essence, 1 part of lemon yellow and 250 parts of water.
The preparation method of the trimebutine maleate resin compound sustained-release suspension comprises the following steps of adding xanthan gum into water, stirring to dissolve the mixture to form viscous liquid, sequentially adding citric acid, propylene glycol, aspartame, methylparaben, lemon essence and lemon yellow, uniformly mixing, adding trimebutine maleate resin compound, stirring at 300rpm for 30min, uniformly mixing, filling into an HDPE bottle, and capping to obtain the trimebutine maleate resin compound sustained-release suspension.
Example 5
The sustained-release trimebutine maleate resin compound suspension comprises, by weight, 200 parts of trimebutine maleate resin compound, 22 parts of xanthan gum, 10 parts of tragacanth, 17 parts of citric acid, 6 parts of propylene glycol, 6 parts of aspartame, 1.5 parts of methylparaben, 0.5 part of lemon essence, 0.5 part of lemon yellow and 250 parts of water.
The preparation method of the trimebutine maleate resin compound sustained-release suspension comprises the following steps of adding xanthan gum and tragacanth into water, stirring to dissolve the xanthan gum and the tragacanth into viscous liquid, sequentially adding citric acid, propylene glycol, aspartame, methylparaben, lemon essence and lemon yellow, uniformly mixing, adding the trimebutine maleate resin compound, stirring at a speed of 300rpm for 30min, uniformly mixing, filling into an HDPE bottle, and capping to obtain the trimebutine maleate resin compound sustained-release suspension.
Example 6
The sustained-release trimebutine maleate resin compound suspension comprises, by weight, 200 parts of trimebutine maleate resin compound, 18 parts of xanthan gum, 20 parts of tragacanth, 15 parts of citric acid, 4 parts of propylene glycol, 4 parts of aspartame, 0.5 part of methylparaben, 1.5 parts of lemon essence, 1.5 parts of lemon yellow and 250 parts of water.
The preparation method of the trimebutine maleate resin compound sustained-release suspension comprises the following steps of adding xanthan gum and tragacanth into water, stirring to dissolve the xanthan gum and the tragacanth into viscous liquid, sequentially adding citric acid, propylene glycol, aspartame, methylparaben, lemon essence and lemon yellow, uniformly mixing, adding the trimebutine maleate resin compound, stirring at a speed of 300rpm for 30min, uniformly mixing, filling into an HDPE bottle, and capping to obtain the trimebutine maleate resin compound sustained-release suspension.
Comparative example 1
The procedure of example 4 was repeated except that the xanthan gum was replaced with gelatin.
Comparative example 2
The procedure of example 4 was repeated except that the xanthan gum was replaced with guar gum.
Comparative example 3
The procedure of example 5 was repeated except that the xanthan gum was replaced with gelatin.
Comparative example 4
The procedure of example 6 was repeated except that the xanthan gum was replaced with guar gum.
Taking the sustained-release suspensions of the trimebutine maleate resin compositions prepared in examples 4-6 and comparative examples 1-4, and examining the wall built-up phenomenon, the particle aggregation phenomenon and the sedimentation volume ratio.
1. Wall hanging experiment, namely standing the suspension prepared in the examples 4-6 and the comparative examples 1-4 for 3 hours, turning the suspension for 7-8 times in the forward and reverse directions, placing the suspension on a horizontal tabletop, and observing whether particles are hung on the inner wall of the inner packaging bottle or not, and whether the particles hung on the inner wall flow into the suspension or not.
It was observed that some particles of the suspension of example 4 were hung on the inner wall and flowed into the suspension within 1min, and that the suspensions of comparative examples 1 to 4 had more particles hanging on the inner wall and still had more particles not flowed into the suspension within 1 min.
2. The method comprises the specific steps of taking the suspensions prepared in examples 4-6 and comparative examples 1-4, reversing the directions for 7-8 times, standing for 3 hours, using a light source to strengthen the visibility of a visual method, using the light source to illuminate the suspensions in an inner packaging bottle, and observing whether loose aggregates exist.
It was observed that the suspensions of examples 4 to 6 all had no particle aggregation, whereas the suspensions of comparative examples 1 to 4 all had particle aggregation.
3. And detecting the sedimentation volume ratio, namely adding 25mL of each group of suspension into a measuring cylinder with a plug, shaking, recording the height H0 at the moment, standing for 3H at 25 ℃, recording the height of a sedimentation surface in the measuring cylinder, calculating the sedimentation volume ratio, measuring in parallel for three times, and recording the average value.
The results are that the sedimentation volume ratios of examples 4-6 are 0.90, 0.93 and 0.98 in sequence, all meet the pharmacopoeia regulations (the sedimentation volume ratio is more than or equal to 0.90), and the sedimentation volume ratios of comparative examples 1-4 are less than 0.90 and do not meet the pharmacopoeia regulations.
From the above results, it can be seen that the trimebutine maleate resin complex can be formulated into suspension and maintained in a stable suspension state by using xanthan gum, and that the stability of the suspension state can be further improved by using xanthan gum and tragacanth gum in combination.
The dissolution test was performed by taking the trimebutine maleate resin composite slow release suspension tested in examples 4-6.
The dissolution method comprises 50rpm paddle method, sampling time of 2, 4, 6, 8, 10 and 12h, dissolution medium of 0.15MNaCl aqueous solution, medium volume of 900ml, and temperature of 37deg.C. When the sample is put into the sample, 10ml of the sample is sampled at a set time point, the isothermal and equal-volume dissolution medium is supplemented, the sample is filtered to obtain a sample solution, and the content of the trimebutine is detected. The results are shown in FIG. 4.
FIG. 4 is the dissolution profile of examples 4-6.
As can be seen from fig. 4, the sustained-release suspension of the trimebutine maleate resin compound prepared by the invention has no burst release phenomenon, the release curve is relatively gentle and is close to zero-order release from the aspect of accumulated release, the total release time is about 10-12 hours, and the drug release period is obviously prolonged compared with the conventional trimebutine preparation.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.